AI summary by TwinMind

Jaykumar Menon | Open Source Pharma and Respiratory Pandemics | Talks at Google

Talks at Google

44m 59s

Introduction & Background

  • Jay Kumar Mainen introduced by Google Assistant team
  • Chair and co-founder of Open Source Pharma Foundation (global non-profit)
  • Human rights litigator background, senior fellow at Harvard Global Health Institute
  • Visiting scientist at Harvard School of Public Health
  • William Rogers Award recipient (Brown's alumnus of the year)
  • Social activist involved in:
    • Freeing wrongly convicted individuals (life sentence and death penalty cases)
    • Addressing iron deficiency in India and Tanzania

Personal Journey to Open Source Pharma

  • Previously worked at Center for Constitutional Rights (NYC)
  • Two main case types: head of state and death row/murder cases
  • Represented Tiananmen Square student leaders, Bosnian genocide victims
  • Organization won cases in Guantanamo at Supreme Court
  • Helped free David Wong as 15th lawyer on case
  • Worked at X Prize Foundation on innovation models for social problems
  • Focused on "giga scale social innovation" affecting 1+ billion people
  • Transformative change through open innovation techniques

Salt Project (Iron Deficiency Solution)

  • 2 billion people worldwide lack sufficient micronutrients (particularly iron)
  • 5 billion people consume iodized salt daily
  • Solution: Added iron to iodized salt
  • Project scaled to 1+ billion meals
  • Cost: 25 cents per person per year
  • Expanding to more nutrients and geographies (Tanzania next)

Village Lab Video Presentation

  • Professor from Kerala, India demonstrating remote research capabilities
  • Students publishing international papers from basic facilities
  • Internet enabling global knowledge access and collaboration
  • Aisha's story: Conservative family background, developed home lab
  • Passion for research enabled by internet connectivity

Open Source Pharma Foundation Overview

  • Only 5% of human diseases have FDA-approved cures
  • Current system oriented toward most lucrative diseases
  • Exponentially declining productivity in pharma sector (Eroom's Law vs Moore's Law)
  • Drug development costs: $2.5+ billion per drug
  • Timeline: 12-17 years development time
  • 95% of ailments lack approved cure/treatment

Open Source Model Application

  • Drawing parallels to software industry (Android, Chrome, Mozilla, Linux)
  • Leveraging billions of people not engaged in drug discovery process
  • Three-step process:
    • Early stages: Online/computer-based (easy for open source)
    • Middle step: Wet labs (crowdsourcing, Airbnb-style networks)
    • Final step: Generic drug industry infrastructure for distribution

Scientific Validation & Partnerships

  • Significant papers published in Nature
  • Government of India involvement
  • 2014 Rockefeller Foundation conference
  • Participants: Big pharma, small pharma, academia, NGOs, computer theorists
  • Initial funding received in 2018
  • Bangalore main office, presence in Paris and New York
  • Goal: Cut costs by 90%+, time by 50%+
  • "Linux for drugs" and "medicine for all" mottos

Tuberculosis Success Case

  • 1/4 of humanity infected with TB bacteria
  • Most widely used TB drug is 50 years old
  • Repurposed diabetes drug metformin for tuberculosis
  • Reached Phase 2b trials in first funded year
  • Cost: Less than $50,000 (several orders of magnitude less than standard pharma)
  • Late stage clinical trials with Government of India

COVID-19 Projects

Antibody Cocktail Project

  • Based on DARPA technology (used by US President)
  • Map, clone, mass produce antibodies from COVID survivors
  • Global network for localized production
  • Small biotechs/hospitals can produce on-site with no royalties
  • Provides ~3 months immunity

Repurposing Hub

  • Nearly every COVID drug in clinical trials is repurposed
  • Lack of infrastructure for repurposing knowledge
  • Partnership with US/Brazil governments, NIH, PhilCruz, EU-backed Actress group
  • Creating global hub for open source approaches

Open Source Drug Discovery Software

  • "Red Hat for medicines"
  • Village lab community needs better software tools
  • Current software is flawed
  • Potential for wave-upon-wave innovation (similar to software industry)

Open Source COVID-19 Vaccine Development

  • All-star cast of Harvard scientists backing concept
  • Paul Farmer and Tachi Yamada (former R&D leader at Gates Foundation, GSK, Takeda)
  • Repurposing old vaccines with open IP for COVID-19

Scientific Mechanism

  • Live attenuated vaccines train innate immunity
  • Provides broad umbrella protection beyond specific pathogen
  • Published in New England Journal of Medicine
  • 100+ years of known broad immunity effects

Real-World Evidence

  • USS Roosevelt case study: 1,000 sailors COVID-positive, only 1 hospitalized
  • Sailors receive MMR vaccine upon enlistment
  • Cross-national studies showing infection rates vs vaccine rates
  • BCG study: 45% reduction in all respiratory infections in elderly

Trial Details

  • 100x cheaper to repurpose existing vaccine vs creating new one
  • Phase 3 trials ready to launch
  • Partners: Open Source Pharma Foundation, Harvard Medical School, Government of India
  • US trial: Nursing homes and elderly population
  • Manufacturing already in place, decades of safety data
  • Vaccines cost as little as 11 cents per dose

Funding Requirements

  • US trial: $3 million
  • India trial: $400,000-$700,000
  • Total package: $10 million for multiple candidates/trials
  • Philanthropic model (no profit motive)
  • Industry doesn't support this type of work

Q&A Session

Revaccination Requirements

  • MMR and BCG vaccines wear off over time
  • Need first-time vaccination or revaccination for protection
  • Still being studied in trials

Implementation Challenges

  • Clinical trials are logistically complex
  • Shortage of epidemiologists and clinical trial specialists
  • Most specialists booked with more remunerative projects
  • Intellectual battle: Repurposing viewed as less prestigious
  • Body is complex system, not simple mechanistic view

Legal Structures

  • "Common heritage of all humankind" principle
  • Open intellectual property - no monopolization possible
  • Multiple producers can compete
  • No hoarding possible
  • Better economically due to competition

Contributor Incentives

  • Similar to software open source model
  • Learning opportunities and recognition
  • Community participation
  • Micro attributions on papers
  • Training for young scientists
  • Professors leverage larger teams

Trial Timeline

  • BCG trial in India already launched (elderly patients)
  • Second India trial: Ethics approvals in weeks
  • US trial: Sites identified, may expand beyond nursing homes
  • First patient enrollment: Matter of weeks after funding

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome